SCYNEXIS

SCYNEXIS Cash Ratio

The Cash Ratio of SCYNEXIS (SCYX) as of Oct 19, 2026 is 3.87. In the previous year, Cash Ratio was 2.22 — a change of 73.79% (higher).

Cash Ratio

3.87

YoY

73.79%

Last updated:

Cash Ratio of SCYNEXIS is 2025 3.87 . Cash Ratio of SCYNEXIS was 2024 2.22 . It decreases by 73.79% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Cash Ratio of SCYNEXIS is 3.87 in 2025.

Cash Ratio of SCYNEXIS changed from 2.22 to 3.87, representing a 73.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Ratio SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

The Cash Ratio is the most conservative liquidity metric, comparing only cash and equivalents to current liabilities.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Ratio's SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SCYNEXIS

All Key Metrics — SCYNEXIS